Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Warner-Lambert Sudafed sales up 7% to $43 mil.; Listerine mouthwash gains 6%.

This article was originally published in The Tan Sheet

Executive Summary

WARNER-LAMBERT SUDAFED SALES GAIN 7% IN THIRD QUARTER to $43 mil., the firm reported Oct. 22. The cold medication, one of Warner-Lambert's best performing consumer health care products in the quarter, recently was extended with Cold & Sinus gelcaps and Children's Chewable tablets. Listerine antiseptic mouthwash grew 6% to $98 mil. in the period, and Nix head lice medication increased 60% to $21 mil. Nix benefitted from an increase in the total head lice treatment category and from wider U.S. distribution

You may also be interested in...



QUOTED. 23 January 2020. John Milad.

Quanta Dialysis is linking up with B. Braun Avitum UK to support patients with Quanta’s personal hemodialysis device in the home. See what Quanta CEO John Milad said about it here.

EU’s Cosmetic Microplastic Restriction Expected To Be ‘Very Wide-Ranging’ At Best

Cosmetics Europe’s Director-General John Chave discusses next steps in the European Union’s proposed drive to ban manufactured microplastic in all cosmetic products. Industry continues to fight for something more proportionate, but it’s up against powerful forces in today’s European theater.

HanAll Advancing Novel Dry Eye Contender Despite Mixed Top-Line

HanAll and Daewoong remain upbeat on dry eye candidate HL036 and are gearing up for a second Phase III US study despite the first missing its primary endpoint in just-released top-line results.

Topics

UsernamePublicRestriction

Register

PS086280

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel